How Exercise Training Affects Insulin Response and Fitness in Type 1 Diabetes and Overweight
Tests an exercise program's effect on fitness and insulin response in type 1 diabetes.
Plain-language title generated from the registry record
Registry title: Impact of Obesity on Microvascular Insulin Action and Cardiorespiratory Fitness in Type 1 Diabetes
Key facts
- Where
- Charlottesville, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 21 and 50 years old?
Source: NCT07573228, who can take part
Where in United States
- University of VirginiaCharlottesville, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Virginia
- Trial code
- NCT07573228
- Record updated
- 7 May 2026
- Original description
The purpose of this study is:Read full original descriptionShow less
Impact of Obesity on Microvascular Insulin Action and Cardiorespiratory Fitness in Type 1 Diabetes (
The purpose of this study is:
* To see if insulin resistance (how sensitive your muscle tissue is to insulin) is associated with lower cardio fitness in people with Type 1 diabetes compared to healthy controls, before and after a High Intensity Interval Training (HIIT) exercise program. * To see if being overweight and having Type 1 diabetes is associated with lower cardio fitness compared to overweight healthy controls, before and after a HIIT exercise program.
Inclusion: • Male or female ≥21 and ≤50 years old; For persons with T1D: Disease duration ≥ 5 years and HbA1c ≤ 8.5% on multiple daily insulin injection or insulin pump; Body mass index: ≥19 and ≤27 kg/m2 for control and T1D, ≥30 and ≤40 kg/m2 (27.5 to 37.5 for Asian Americans) for obesity and T1D + obesity. BMI is limited to ≤40 kg/m2 (37.5 for Asian Americans) for easier vascular access and cardiac imaging; Stable use of non-insulin medications for over 6 months other than estrogen/progesterone containing medications which must be discontinued at least 3 months prior to the study (intrauterine devices may be continued due to limited systemic absorption).
Exclusion: • Acute or chronic disease other than T1D or obesity; History of microvascular or macrovascular diabetes complications; History of diabetic ketoacidosis in the past 24 months; History of hypoglycemia unawareness; Recently active (>20 min of moderate/high intensity exercise, 2 times/week); Subjects who are smokers or who have quit smoking <5 years; Subjects with hypertriglyceridemia (>400 mg/dl); Current use of vasoactive medications (i.e. calcium channel blockers, angiotensin-converting enzyme or renin inhibitors, angiotensin-receptor blockers, nitrates, alpha- or beta-blockers, or diuretics); Females taking oral contraceptives in the past 3 months; Subjects with a history of significant metabolic, cardiac, cerebrovascular, hematological, pulmonary, gastrointestinal, liver, renal, or endocrine disease or malignancy; Pregnant (as evidenced by positive pregnancy test) or nursing women; Musculoskeletal condition preventing participation in exercise testing or exercise training; History of gastroparesis; Pulse oximetry <90%.